Sector
Healthcare
Industry
Medical - Devices
Employees
120
First IPO Date
April 17, 2019
| Name | Title | Pay | Year Born |
| Hadar Levy | Chief Executive Officer | 542,495 | 1974 |
| David Zacut | Co-Founder & Vice-Chairman | 40,246 | 1953 |
| Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director | 69,921 | 1970 |
| Yiftach Roth | Founder & Chief Scientific Officer | 108,000 | 1971 |
| Ido Marom | Chief Financial Officer | 303,199 | 1976 |
| Colleen Hanlon | Vice President of Medical Affairs | 327,488 | 1980 |
| Michael Cohen | Vice President of US Sales | 397,438 | N/A |
| Dor Hagai | Vice President of Operations | 0 | N/A |
| Menachem C. Klein | Vice President, General Counsel & Corporate Secretary | 0 | N/A |
| Gilead Moiseyev | Chief Technology Officer | 0 | 1972 |
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.